Immunization Using Polysialic Acid-KLH [keyhole limpet haemocyanin] or N-Propionylated Polysialic Acid-KLH Conjugate Plus the Immunological Adjuvant QS-21 in Patients With Small Cell Lung Cancer Who Have Achieved a Major Response to Initial Therapy
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Lung cancer vaccine; QS 21
- Indications Small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 19 Jun 2013 Biomarkers information updated
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2005 New trial record.